Future Fund LLC Purchases 350 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Future Fund LLC grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 20.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,052 shares of the pharmaceutical company’s stock after purchasing an additional 350 shares during the period. Vertex Pharmaceuticals comprises approximately 2.4% of Future Fund LLC’s investment portfolio, making the stock its 22nd biggest holding. Future Fund LLC’s holdings in Vertex Pharmaceuticals were worth $826,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Dunhill Financial LLC raised its stake in shares of Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 24 shares in the last quarter. Legacy Investment Solutions LLC bought a new stake in shares of Vertex Pharmaceuticals during the third quarter worth approximately $33,000. Brown Lisle Cummings Inc. acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $30,000. Truvestments Capital LLC bought a new position in shares of Vertex Pharmaceuticals during the third quarter worth approximately $35,000. Finally, Capital Performance Advisors LLP acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth approximately $39,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $488.29 on Monday. The stock has a market cap of $125.39 billion, a price-to-earnings ratio of -221.95, a P/E/G ratio of 2.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The company has a 50 day simple moving average of $448.27 and a 200 day simple moving average of $461.15. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 530 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $475.34, for a total transaction of $251,930.20. Following the sale, the executive vice president now directly owns 58,539 shares of the company’s stock, valued at $27,825,928.26. The trade was a 0.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders sold 1,084 shares of company stock worth $505,512. 0.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on VRTX shares. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Citigroup started coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $575.00 price target on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a research note on Monday, December 23rd. Scotiabank increased their target price on shares of Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $506.70.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.